+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Radiopharmaceuticals - Global Strategic Business Report

  • PDF Icon

    Report

  • 739 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 835008

New Therapeutic Radiopharmaceuticals to Drive Global Market

Global Radiopharmaceuticals Market to Reach $14.3 Billion by 2030

The global market for Radiopharmaceuticals estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$14.3 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2022-2030. SPECT Radioisotopes, one of the segments analyzed in the report, is projected to record 10.4% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the Pet Radioisotopes segment is estimated at 9.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $3.1 Billion, While China is Forecast to Grow at 13.9% CAGR

The Radiopharmaceuticals market in the U.S. is estimated at US$3.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8% and 8.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Select Competitors (Total 141 Featured)

  • Actinium Pharmaceuticals, Inc.
  • Advanced Accelerator Applications
  • Alliance Medical Ltd.
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Cardinal Health, Inc.
  • Curium US LLC
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Jubilant DraxImage Inc.
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd.
  • Nordion Inc.
  • Radiopharm Theranostics Ltd.
  • Siemens Healthcare GmbH

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

What`s New?

  • Special discussions on the global economic climate and market sentiment
  • Coverage on global competitiveness and key competitor percentage market shares
  • Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and trademarked research platform
  • Complimentary updates for one year
  • Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Frequently Asked Questions about the Radiopharmaceuticals Market

What is the estimated value of the Radiopharmaceuticals Market?

The Radiopharmaceuticals Market was estimated to be valued at $6.3 Billion in 2022.

What is the growth rate of the Radiopharmaceuticals Market?

The growth rate of the Radiopharmaceuticals Market is 10.8%, with an estimated value of $14.3 Billion by 2030.

What is the forecasted size of the Radiopharmaceuticals Market?

The Radiopharmaceuticals Market is estimated to be worth $14.3 Billion by 2030.

Who are the key companies in the Radiopharmaceuticals Market?

Key companies in the Radiopharmaceuticals Market include Actinium Pharmaceuticals, Inc., Advanced Accelerator Applications, Alliance Medical Ltd., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics, Inc., Cardinal Health, Inc., Curium US LLC, GE Healthcare, IBA Radiopharma Solutions and Jubilant DraxImage Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Radiopharmaceuticals: A Prelude
  • Mechanism of Action
  • Global Economic Update
  • From Pandemic to War & Inflation: “Subdued Outlook for 2023 Despite Signs of Easing Inflationary Conditions”
  • Here’s How Inflationary Pressures Affect the Economy
  • Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue
  • Slower Than Anticipated Decline Makes Inflation a Stickier Than Expected Problem to Solve in 2023: Global Inflation Rates (In %) for the Years 2019 Through 2024
  • Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Anti-Inflation Fiscal Policies & Slower Than Desirable Easing of Inflationary Pressures: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024
  • Pandemic-Led Disruptions Affect Radiopharmaceuticals Supply
  • Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in US Hospitals
  • Hospitals Struggle as Distribution Bottlenecks Affect Supply of Medical Radioisotopes
  • Nuclear Medicine Services Back to Normal
  • Pandemic Presents Generational Opportunity
  • Global Market Outlook
  • Key Market Drivers
  • Market Restraints
  • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
  • Classification of Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals: The Dominant Segment
  • Positron Emission Tomography (PET)
  • Single Photon Emission Computed Tomography (SPECT)
  • Therapeutic Radiopharmaceuticals
  • Supply Shortages Remain a Challenge to Market Growth
  • A Glimpse at Mo-99 Processors Worldwide
  • Nuclear Research Reactor Irradiators Worldwide: A Snapshot
  • Competition
  • Radiopharmaceuticals - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
  • Radiopharmaceuticals Become Promising for Cancer Theranostics
  • Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
  • Notable Clinical Applications of Radiopharmaceuticals in Nuclear Medicine
  • Advent of New Radiopharmaceuticals Widen Scope
  • Startups Develop Unique Radiopharmaceutical Solutions
  • Potential Role of Carbon Dots in Imaging and Theranostics
  • Nano Radiopharmaceuticals: Promising Role in Therapeutic and Imaging Applications
  • Current Major Focus Areas in Radiopharmaceutical Research
  • R&D Efforts in the Radiopharmaceuticals Market
  • Researchers Develop New Nanoparticles to Improve Radiopharmaceutical Efficiency
  • Oncoinvent and NPL Develop Unique Method to Measure & Deliver Dosages in Radiotherapy
  • Researchers Develop S-Value Database for Simplifying Complexity in Tumor Dosimetry
  • Key Impediments in Academic Research of Radiopharmaceuticals
  • Industry Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
  • Role of Radiopharmaceuticals as Diagnostic Technology
  • Promising Molecular Imaging Technology Advancements for SPECT and PET
  • PET Eclipses SPECT in Cardiovascular Imaging
  • Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2023E
  • Cardiac Amyloidosis Visualization: A Potential Application for PET
  • Innovative Radiopharmaceuticals to Boost Cardiac Applications
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Global Annual Medical Cost of Cardiovascular Diseases in US$ Billion (2010-2030)
  • Radiopharmaceuticals: Direct and Targeted Approach for Cancer Treatment
  • Increased Use of Radiopharmaceuticals Across Oncology to Drive Market Growth
  • Rising Cancer Incidence Worldwide Spurs Demand
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020
  • Number of New Cancer Cases and Deaths (in Million) by Region for 2020
  • Intra-Operative Lymphatic Mapping (ILM) Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
  • Growing Prominence of Therapeutic Radiopharmaceuticals for Cancer Care
  • Radiopharmaceuticals Expand Horizons for Cancer Treatment Arena
  • Radiopharmaceuticals as Potential Silver Bullet to Target & Treat Prostate Cancer
  • Challenges with Radiopharmaceuticals for Cancer
  • Rise in Incidence of Neurological Disorders to Drive Growth
  • Application of PET in Drug Development to Expand Opportunities
  • Personalized Medicine Drives Nuclear Medicine
  • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
  • Global Personalized Medicines Market (in US$ Billion) for the Years 2022, 2025 and 2028
  • Need for Guidance for Manufacture of Investigational Radiopharmaceuticals for Clinical Trials
  • Technetium-99m to Hold Immense Potential for Use in Diagnostic Nuclear Medicine in the Future
  • Shortage of 99Mo and 99mTc to Adversely Impact Provider Care and Patient Access
  • Novel Production Method Promises to End Problems of 99mTc Shortages
  • New Approach for Production of Clinical Radiopharmaceuticals
  • Gallium-68-labeled Radiopharmaceuticals: Production & Administering Challenges
  • Radiopharmaceuticals for COVID-19: Role in Diagnosis, Prognosis, and Therapeutic Uses
  • Arti?cial Intelligence: A Promising Tool in Radiotherapy and Radiopharmaceuticals
  • Nuclear Medicine & AI to Power the Future of Precision Medicine
  • Aging Global Population: A Vital Demography
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Rise in Healthcare Expenditure to Drive Growth
  • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 & 2023
  • Relevant Aspects of Radiopharmaceutical Production
  • Regulatory Regime Governing Production and Use of Radiopharmaceuticals
  • The Facilitating Innovative Nuclear Diagnostics (FIND) Act, 2021
  • Challenges Facing Nuclear Medicine Industry
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 3: World 14-Year Perspective for SPECT Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 6: World 14-Year Perspective for PET Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 9: World 14-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 12: World 14-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 15: World 14-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 18: World 14-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 21: World 14-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Endocrine Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Endocrine Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 24: World 14-Year Perspective for Endocrine Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 27: World 14-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 30: World 14-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 33: World 14-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 36: World 14-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 39: World 14-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2023 & 2030
  • TABLE 40: World Radiopharmaceuticals Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 43: World 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Market Overview
  • Increasing Incidence of Cancer: A Major Growth Driver
  • Estimated Number of New Cancer Cases in the US by Gender and Affected Site for 2023
  • Estimated Number of Cancer-Related Deaths in the US by Gender and Body Site for 2023
  • Estimated Number of New Cancer Cases in the US by State for 2023
  • Estimated Number of Cancer-Related Deaths in the US by State for 2023
  • Cardiovascular Imaging Drives Growth
  • Radiopharmaceuticals Usage Grows in PET Imaging
  • Radioisotope/Radiopharmaceuticals Supply Scenario
  • CANADA
  • Market Overview
  • JAPAN
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Market Overview
  • CHINA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Market Overview
  • EUROPE
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Market Overview
  • FRANCE
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Market Overview
  • AUSTRALIA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • Market Overview
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Actinium Pharmaceuticals, Inc.
  • Advanced Accelerator Applications
  • Alliance Medical Ltd.
  • Bayer HealthCare Pharmaceuticals
  • Bracco Diagnostics, Inc.
  • Cardinal Health, Inc.
  • Curium US LLC
  • GE Healthcare
  • IBA Radiopharma Solutions
  • Jubilant DraxImage Inc.
  • Lantheus Medical Imaging Inc.
  • Medi-Radiopharma Ltd.
  • Nordion Inc.
  • Radiopharm Theranostics Ltd.
  • Siemens Healthcare GmbH